Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534078 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01534078: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01534078 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01534078, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
Brentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a chemotherapy molecule. Brentuximab works by using the antibody portion to enter into the Hodgkin lymphoma cells and then releasing the chemotherapy portion, which attempts to destroy the cell. The intravenous chemotherapy drugs Adriamycin, Vinblastine and Dacarbazine (AVD) which you will receive in this research study are approved for use in people with Hodgkin Lymphoma. A drug called bleomycin is usually included with AVD, but since it appears to be a less effective drug with significant potential risks, it is being replaced in this study with the drug brentuximab. In this research study, the investigators are looking to see whether brentuximab in combination with AVD is effective in treating limited-stage Hodgkin Lymphoma.
Interventions
- DRUG Brentuximab Vedotin
- DRUG Adriamycin, vinblastine, and dacarbazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-03 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01534078
The ClinicalTrials.gov registry entry for NCT01534078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brentuximab Vedotin is the first listed.
NCT01534078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01534078 about?
NCT01534078 is a clinical study titled "Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma". Brentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a chemotherapy molecule. Brentuximab works by using the antibody portion to enter into the Hodgkin lymphoma cells and then releasing the chemotherapy portion, which attempts t...
What is the current status of trial NCT01534078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2012-03. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01534078?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Adriamycin, vinblastine, and dacarbazine (DRUG).
Who is sponsoring clinical trial NCT01534078?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.